Selective β2-AR Antagonism in Asthma

Summary

The objectives are to assess the safety, tolerability and effect on the airways of TR4 in patients with mild-to-moderate asthma. The Phase 1 trial is randomised, double-blind, placebo-controlled, and ascending-dose in design.

Timeline

Start

2018-02-28

Primary completion

2022-08-16

Completion

2022-08-16

Drugs

Indications